Quantcast

Latest Bristol-Myers Squibb Stories

2014-02-13 04:20:48

Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES, France and BANGALORE, India, February 13, 2014 /PRNewswire/ -- Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and...

2014-02-12 12:31:53

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - Current and Future Players PharmaPoint: Type 2 Diabetes - Current and Future Players Summary GlobalData has released its pharma report, "PharmaPoint: Type 2 Diabetes - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Type 2 Diabetes Market. The report...

2014-02-12 12:30:26

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Brazilian Pharmaceutical Market 2014-2024Report DetailsDrug selling in Brazil - this new analysis shows you trends, opportunities, and revenuesDo you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts.So...

2014-02-10 16:26:58

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today the Company has obtained exclusive rights to Cynviloq(TM) (marketed as Genexol-PM(®) in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation. Sorrento already has exclusive rights from Samyang for...

2014-02-05 23:23:03

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU report provide analysis of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas. Dallas, Texas (PRWEB) February 05, 2014 Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in a healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years, several new...

2014-02-05 08:30:28

SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Barry Greene to its board of directors. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. He is currently president and chief operating officer of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), a leader in RNAi therapeutics. The appointment increases Ambrx's board membership to six. "Barry joins Ambrx's board at a very exciting time for...

2014-01-29 16:29:02

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/2qlc2k/lexicons_lx4211) has announced the addition of the "Lexicon's LX4211 - FDA canagliflozin decision is key bellweather" [http://www.researchandmarkets.com/research/2qlc2k/lexicons_lx4211 ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) LX4211 is part of a new class of type 2 diabetes agents that inhibit the SGLT2...

2014-01-29 08:29:55

CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ -- Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (NYSE: BMY) for the use of Immuneering's proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines. Terms of agreement were not disclosed. (Logo: http://photos.prnewswire.com/prnh/20140129/NE54258LOGO ) "It is a pleasure to...

2014-01-24 16:22:06

MIAMI, Jan. 24, 2014 /PRNewswire/ -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List. As a result of this new status,...

2014-01-18 08:20:15

Research findings enable disease molecular sub-typing to lead to more informed clinical decision-making IRVING, Texas, Jan. 18, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer (CRC) at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.